Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Significant Growth in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,760,000 shares, a growth of 439.5% from the January 15th total of 326,200 shares. Based on an average daily volume of 6,950,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 4.8% of the shares of the company are short sold.

Hedge Funds Weigh In On Cardio Diagnostics

An institutional investor recently raised its position in Cardio Diagnostics stock. Geode Capital Management LLC boosted its stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 97.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 364,387 shares of the company’s stock after purchasing an additional 179,978 shares during the period. Geode Capital Management LLC owned approximately 0.90% of Cardio Diagnostics worth $334,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Trading Down 0.3 %

CDIO stock opened at $0.53 on Thursday. The firm has a 50 day moving average of $0.74 and a 200 day moving average of $0.46. Cardio Diagnostics has a 52 week low of $0.19 and a 52 week high of $1.91.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.